Link-Asia International MedTech Group Limited Logo

Link-Asia International MedTech Group Limited

1143.HK

(1.2)
Stock Price

0,36 HKD

0.77% ROA

1.26% ROE

73.99x PER

Market Cap.

474.105.570,00 HKD

3.47% DER

0% Yield

1.15% NPM

Link-Asia International MedTech Group Limited Stock Analysis

Link-Asia International MedTech Group Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Link-Asia International MedTech Group Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.63x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (14%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

Negative ROE (-14.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-8.8%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-9), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Link-Asia International MedTech Group Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Link-Asia International MedTech Group Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Link-Asia International MedTech Group Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Link-Asia International MedTech Group Limited Revenue
Year Revenue Growth
2009 821.898.000
2010 1.145.542.000 28.25%
2011 1.309.390.000 12.51%
2012 1.458.192.000 10.2%
2013 1.825.542.000 20.12%
2014 1.032.957.000 -76.73%
2015 1.008.561.000 -2.42%
2016 748.749.000 -34.7%
2017 662.208.000 -13.07%
2018 681.482.000 2.83%
2019 629.948.000 -8.18%
2019 629.948.000 0%
2020 595.023.000 -5.87%
2021 675.523.000 11.92%
2022 529.251.000 -27.64%
2023 501.999.000 -5.43%
2024 1.058.791.996 52.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Link-Asia International MedTech Group Limited Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 45.332.000 100%
2014 35.811.000 -26.59%
2015 33.641.000 -6.45%
2016 29.550.000 -13.84%
2017 24.228.000 -21.97%
2018 19.863.000 -21.98%
2019 0 0%
2019 17.664.000 100%
2020 13.946.000 -26.66%
2021 15.006.000 7.06%
2022 14.511.000 -3.41%
2023 13.209.000 -9.86%
2024 21.504.000 38.57%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Link-Asia International MedTech Group Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 52.996.000
2010 79.086.000 32.99%
2011 91.562.000 13.63%
2012 125.378.000 26.97%
2013 132.883.000 5.65%
2014 75.303.000 -76.46%
2015 76.573.000 1.66%
2016 131.419.999 41.73%
2017 151.491.000 13.25%
2018 182.509.000 17%
2019 179.414.000 -1.73%
2019 179.414.000 0%
2020 178.158.000 -0.7%
2021 153.230.000 -16.27%
2022 105.039.000 -45.88%
2023 88.776.000 -18.32%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Link-Asia International MedTech Group Limited EBITDA
Year EBITDA Growth
2009 103.123.000
2010 93.433.000 -10.37%
2011 100.231.000 6.78%
2012 65.129.000 -53.9%
2013 86.083.000 24.34%
2014 87.119.000 1.19%
2015 84.634.000 -2.94%
2016 -36.879.000 329.49%
2017 -39.780.000 7.29%
2018 -60.132.000 33.85%
2019 -106.275.000 43.42%
2019 -90.556.000 -17.36%
2020 -88.785.000 -1.99%
2021 -30.868.000 -187.63%
2022 -26.767.000 -15.32%
2023 21.123.000 226.72%
2024 106.520.000 80.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Link-Asia International MedTech Group Limited Gross Profit
Year Gross Profit Growth
2009 187.732.000
2010 252.613.000 25.68%
2011 269.331.000 6.21%
2012 281.329.000 4.26%
2013 373.264.000 24.63%
2014 225.477.000 -65.54%
2015 212.094.000 -6.31%
2016 149.914.000 -41.48%
2017 164.415.000 8.82%
2018 147.274.001 -11.64%
2019 135.842.000 -8.42%
2019 135.842.000 0%
2020 154.712.000 12.2%
2021 144.888.000 -6.78%
2022 101.396.000 -42.89%
2023 136.867.000 25.92%
2024 294.895.996 53.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Link-Asia International MedTech Group Limited Net Profit
Year Net Profit Growth
2009 76.216.000
2010 69.921.000 -9%
2011 57.051.000 -22.56%
2012 23.345.000 -144.38%
2013 28.566.000 18.28%
2014 89.986.000 68.26%
2015 77.588.000 -15.98%
2016 -82.646.000 193.88%
2017 -128.428.000 35.65%
2018 -73.875.000 -73.85%
2019 -164.588.000 55.12%
2019 -171.735.000 4.16%
2020 -173.052.000 0.76%
2021 -46.397.000 -272.98%
2022 -54.042.000 14.15%
2023 5.257.000 1128%
2024 -15.632.000 133.63%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Link-Asia International MedTech Group Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 5
2010 5 0%
2011 3 -100%
2012 1 -100%
2013 1 0%
2014 4 75%
2015 3 -33.33%
2016 -3 200%
2017 -5 40%
2018 -2 -150%
2019 -55 96.36%
2019 -6 -1000%
2020 -5 -25%
2021 -1 0%
2022 -1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Link-Asia International MedTech Group Limited Free Cashflow
Year Free Cashflow Growth
2009 82.497.000
2010 13.755.000 -499.76%
2011 18.706.000 26.47%
2012 18.604.000 -0.55%
2013 6.940.000 -168.07%
2014 35.609.000 80.51%
2015 -10.651.000 434.33%
2016 -14.012.000 23.99%
2017 -42.221.000 66.81%
2018 -136.930.000 69.17%
2019 -17.898.500 -665.04%
2019 -70.355.000 74.56%
2020 -45.852.000 -53.44%
2021 -122.547.000 62.58%
2022 99.599.000 223.04%
2023 -36.881.000 370.06%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Link-Asia International MedTech Group Limited Operating Cashflow
Year Operating Cashflow Growth
2009 99.300.000
2010 29.981.000 -231.21%
2011 38.326.000 21.77%
2012 35.466.000 -8.06%
2013 21.206.000 -67.25%
2014 61.766.000 65.67%
2015 15.416.000 -300.66%
2016 -6.415.000 340.31%
2017 -36.214.000 82.29%
2018 -95.791.000 62.19%
2019 -15.597.500 -514.14%
2019 -61.151.000 74.49%
2020 -15.040.000 -306.59%
2021 -100.449.000 85.03%
2022 107.554.000 193.39%
2023 -34.907.000 408.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Link-Asia International MedTech Group Limited Capital Expenditure
Year Capital Expenditure Growth
2009 16.803.000
2010 16.226.000 -3.56%
2011 19.620.000 17.3%
2012 16.862.000 -16.36%
2013 14.266.000 -18.2%
2014 26.157.000 45.46%
2015 26.067.000 -0.35%
2016 7.597.000 -243.12%
2017 6.007.000 -26.47%
2018 41.139.000 85.4%
2019 2.301.000 -1687.87%
2019 9.204.000 75%
2020 30.812.000 70.13%
2021 22.098.000 -39.43%
2022 7.955.000 -177.79%
2023 1.974.000 -302.99%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Link-Asia International MedTech Group Limited Equity
Year Equity Growth
2009 145.870.000
2010 172.271.000 15.33%
2011 347.975.000 50.49%
2012 363.781.000 4.34%
2013 390.390.000 6.82%
2014 351.547.000 -11.05%
2015 548.001.999 35.85%
2016 463.637.000 -18.2%
2017 654.002.000 29.11%
2018 582.832.000 -12.21%
2019 411.013.000 -41.8%
2020 295.934.000 -38.89%
2021 365.998.000 19.14%
2022 362.016.000 -1.1%
2023 488.724.999 25.93%
2023 449.653.000 -8.69%
2024 497.456.000 9.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Link-Asia International MedTech Group Limited Assets
Year Assets Growth
2009 471.637.000
2010 520.134.000 9.32%
2011 771.530.000 32.58%
2012 861.896.000 10.48%
2013 1.145.813.000 24.78%
2014 1.092.094.000 -4.92%
2015 853.448.000 -27.96%
2016 800.284.000 -6.64%
2017 960.588.000 16.69%
2018 930.862.000 -3.19%
2019 734.840.000 -26.68%
2020 657.405.000 -11.78%
2021 677.978.000 3.03%
2022 659.233.000 -2.84%
2023 776.418.000 15.09%
2023 716.849.000 -8.31%
2024 798.098.000 10.18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Link-Asia International MedTech Group Limited Liabilities
Year Liabilities Growth
2009 325.767.000
2010 347.863.000 6.35%
2011 423.555.000 17.87%
2012 498.115.000 14.97%
2013 704.480.000 29.29%
2014 740.547.000 4.87%
2015 305.446.000 -142.45%
2016 336.647.000 9.27%
2017 306.586.000 -9.81%
2018 348.030.000 11.91%
2019 323.827.000 -7.47%
2020 361.471.000 10.41%
2021 311.980.000 -15.86%
2022 297.217.000 -4.97%
2023 287.693.000 -3.31%
2023 267.196.000 -7.67%
2024 300.642.000 11.12%

Link-Asia International MedTech Group Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.7
Net Income per Share
0.03
Price to Earning Ratio
73.99x
Price To Sales Ratio
0.88x
POCF Ratio
-3.63
PFCF Ratio
-3.68
Price to Book Ratio
0.92
EV to Sales
0.43
EV Over EBITDA
5.23
EV to Operating CashFlow
-1.85
EV to FreeCashFlow
-1.81
Earnings Yield
0.01
FreeCashFlow Yield
-0.27
Market Cap
0,47 Bil.
Enterprise Value
0,23 Bil.
Graham Number
1.32
Graham NetNet
0.7

Income Statement Metrics

Net Income per Share
0.03
Income Quality
-23.96
ROE
0.01
Return On Assets
0.01
Return On Capital Employed
0.04
Net Income per EBT
0.76
EBT Per Ebit
0.41
Ebit per Revenue
0.04
Effective Tax Rate
0.5

Margins

Sales, General, & Administrative to Revenue
0.07
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.29
Operating Profit Margin
0.04
Pretax Profit Margin
0.02
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.63
Free CashFlow per Share
-0.64
Capex to Operating CashFlow
-0.02
Capex to Revenue
0.01
Capex to Depreciation
0.09
Return on Invested Capital
0.02
Return on Tangible Assets
0.01
Days Sales Outstanding
115.52
Days Payables Outstanding
48.84
Days of Inventory on Hand
39.05
Receivables Turnover
3.16
Payables Turnover
7.47
Inventory Turnover
9.35
Capex per Share
0.01

Balance Sheet

Cash per Share
1,47
Book Value per Share
2,49
Tangible Book Value per Share
2.49
Shareholders Equity per Share
2.49
Interest Debt per Share
0.11
Debt to Equity
0.03
Debt to Assets
0.02
Net Debt to EBITDA
-5.42
Current Ratio
2.79
Tangible Asset Value
0,50 Bil.
Net Current Asset Value
0,44 Bil.
Invested Capital
528628000
Working Capital
0,48 Bil.
Intangibles to Total Assets
0
Average Receivables
0,17 Bil.
Average Payables
0,06 Bil.
Average Inventory
47780000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Link-Asia International MedTech Group Limited Dividends
Year Dividends Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%

Link-Asia International MedTech Group Limited Profile

About Link-Asia International MedTech Group Limited

Link-Asia International MedTech Group Limited, an investment holding company, provides electronic manufacturing services (EMS) for the telecommunications, security, car electronics, home appliances, other consumer, and industrial electronic products. The company operates through four segments: EMS, Distribution of Communications Products, Securities and Other Assets Investment, and Real Estate Supply Chain Services. It is also involved in the trade of personal care products, business telephone systems, and telecommunication products; manufacture and sale of telecommunications and other products, and consumable electronic products; sale of audio equipment; and provision of consultancy services, as well as pre-pregnancy care and assisted reproductive services. In addition, the company offers equity investment and property agency services; and real estate advisory and purchase services. It operates in the People's Republic of China, the United States, Switzerland, France, Poland, the United Kingdom, Belgium, Russia, Thailand, Malaysia, Brazil, and internationally. The company was formerly known as Link-Asia International Co. Ltd. and changed its name to Link-Asia International MedTech Group Limited in December 2020. Link-Asia International MedTech Group Limited was founded in 1992 and is headquartered in Tsim Sha Tsui, Hong Kong.

CEO
Mr. Xavier Dupont
Employee
820
Address
Tower 6
Tsim Sha Tsui,

Link-Asia International MedTech Group Limited Executives & BODs

Link-Asia International MedTech Group Limited Executives & BODs
# Name Age
1 Mr. Xavier Dupont
Chief Executive Officer of M&F Holdings Ltd.
70
2 Ms. Mei Chu Tam
Company Secretary
70
3 Mr. Qi Wang
Executive Director
70
4 Ms. Sulan Bian
Executive Director
70
5 Mr. Dailian Lin
Executive Chairman
70
6 Ms. Xiaoshan Lin
Executive Director
70
7 Mr. Zhiwei Liu
Executive Director
70

Link-Asia International MedTech Group Limited Competitors